# Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia

> **NCT00505258** · PHASE2 · WITHDRAWN · sponsor: **Basilea Pharmaceutica**

## Conditions studied

- Bacteremia

## Interventions

- **DRUG:** ceftobiprole medocaril

## Key facts

- **NCT ID:** NCT00505258
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2009-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was withdrawn due to lack of an appropriate patient population.
- **Last updated:** 2013-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00505258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00505258, "Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00505258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*